Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 7/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | GAA | P10253 | 3/20 | 0.73 |
| ▸ | HTT | P42858 | 3/20 | 0.73 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13147771 | 0.86 | HPGD (0.83) | CSF1RALDH1A1GAAHTTMAPK10 | |
| SCHEMBL13147762 | 0.86 | CSF1R (1.00) | CSF1RALDH1A1GAAHTTMAPK10 | |
| SCHEMBL13148069 | 0.86 | CSF1R (1.00) | CSF1RALDH1A1GAAHTTMAPK10 | |
| SCHEMBL13167004 | 0.84 | ALDH1A1 (1.00) | CSF1RALDH1A1GAAHTTMAPK10 | |
| SCHEMBL13147773 | 0.84 | CSF1R (0.67) | CSF1RALDH1A1GAAHTTMAPK10 | |
| SCHEMBL13147776 | 0.84 | CSF1R (1.00) | CSF1RALDH1A1GAAHTTMAPK10 | |
| SCHEMBL13148088 | 0.84 | CSF1R (1.00) | CSF1RALDH1A1GAAHTTMAPK10 | |
| SCHEMBL13148038 | 0.82 | CSF1R (1.00) | CSF1RALDH1A1GAAHTTPOLB | |
| SCHEMBL5093277 | 0.82 | CSF1R (1.00) | CSF1RALDH1A1GAAHTTPOLB | |
| SCHEMBL13147758 | 0.78 | CSF1R (1.00) | CSF1RALDH1A1GAAHTTMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | claimed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | CSF1R 111/4885ALDH1A1 4731/4885GAA 4492/4885 |
| US-20050004112-A1 | C-fms kinase inhibitors | FLT3, FGR, FER | CSF1R 76/4885ALDH1A1 4574/4885GAA 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.